Belgian biotech ThromboGenics has announced it will change its name to Oxurion in the next few weeks. The stock ticker symbol will change to OXUR.
Chief executive Patrik De Haes said: “The new name, Oxurion, is designed to better reflect our ambition to deliver best in class therapies for back of the eye disorders,” and “we are also expanding our drug development efforts into new back of the eye indications where there is clear need for improved therapeutic options.”
Source: The Pharma Letter
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
